Who
Sumita Ray
Chief Legal Compliance Officer
Company insider
Files Form 4 as: Chief Legal Compliance Officer, Cue Biopharma; Director, Biomea Fusion; Chief Legal, Comp & Admin Off, Vaxxinity; Chief Legal and Admin Officer, Instil Bio; Officer, Calithera Biosciences; Chief Compliance Officer, Pharmacyclics.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $583K
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 24 Jun 2013
- Last trade
- 12 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 14 Oct 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $52K1,844 at $28.05 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code M | —18,196 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $70K2,383 at $29.37 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $196K6,442 at $30.35 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,196 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $1254 at $31.13 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,196 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code M | —18,196 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $70K2,383 at $29.37 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $196K6,442 at $30.35 | filing |
| 13 Aug 2026filed 17 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $1254 at $31.13 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code A | —54,589 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,589 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,589 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code A | —54,589 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —196,299 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —196,299 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,970 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,025 at $0.00 | filing |
| 1 Nov 2023filed 29 Apr 2024 | Vaxxinityoption or derivative | SEC FORM 4 Code A | —425,000 at $0.00 | filing |
News
Cue Biopharma (NASDAQ:CUE) Stock: Insider Michael Vincent Meluzio Sells 1,144 SharesCUE · dailypolitical.com · 15 Oct 2026Cue Biopharma (NASDAQ:CUE) Insider Sells $51,724.20 in StockCUE · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Sumita Ray; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.